docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2022-21-7-6-11docru-77Research ArticleПУЛЬМОНОЛОГИЯPULMONOLOGYМеханизмы развития легочной гипертензии у детей с бронхолегочной дисплазиейMechanisms of Development of Pulmonary Hypertension in Children with Bronchopulmonary Dysplasiahttps://orcid.org/0000-0002-0784-0155СеливерстоваА. А.SeliverstovaA. A.

Селиверстова Алина Анатольевна  — врач-неонатолог отделения патологии новорожденных детей, младший научный сотрудник лаборатории неонатологии и проблем здоровья раннего детского возраста

119296, г. Москва, Ломоносовский пр-т, д. 2/62

2/62 Lomonosovsky Ave., Moscow, 119296

seliverstova_aa@mail.ruhttps://orcid.org/0000-0002-7780-6737ДавыдоваИ. В.DavydovaI. V.

Давыдова Ирина Владимировна — д. м. н., врач-пульмонолог, главный научный сотрудник лаборатории неонатологии и проблем здоровья раннего детского возраста

119296, г. Москва, Ломоносовский пр-т, д. 2/62

2/62 Lomonosovsky Ave., Moscow, 119296

davydova@nczd.ruhttps://orcid.org/0000-0003-8207-6668БасаргинаМ. А.BasarginaM. A.

Басаргина Милана Александровна  — к. м. н., старший научный сотрудник лаборатории неонатологии и проблем здоровья раннего детского возраста, заведующая отделением патологии новорожденных детей

119296, г. Москва, Ломоносовский пр-т, д. 2/62

2/62 Lomonosovsky Ave., Moscow, 119296

basargina.ma@nczd.ruhttps://orcid.org/0000-0001-8586-7946ФисенкоА. П.FisenkoA. P.

Фисенко Андрей Петрович  — д. м. н., профессор, директор

119296, г. Москва, Ломоносовский пр-т, д. 2/62

2/62 Lomonosovsky Ave., Moscow, 119296

director@nczd.ruСемикинаЕ. Л.SemikinaE. L.

Семикина Елена Леонидовна — д. м. н., главный научный сотрудник лаборатории экспериментальной иммунологии и вирусологии, заведующая лабораторным отделом

119296, г. Москва, Ломоносовский пр-т, д. 2/62

2/62 Lomonosovsky Ave., Moscow, 119296

semikina@nczd.ruФГАУ «Национальный медицинский исследовательский центр здоровья детей» Министерства здравоохранения РоссийскойРоссияNational Medical Research Center for Children's HealthRussian Federation202215022025217ПЕДИАТРИЯ611Copyright © Селиверстова А.А., Давыдова И.В., Басаргина М.А., Фисенко А.П., Семикина Е.Л., 20252025Селиверстова А.А., Давыдова И.В., Басаргина М.А., Фисенко А.П., Семикина Е.Л.Seliverstova A.A., Davydova I.V., Basargina M.A., Fisenko A.P., Semikina E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/77Цель обзора

Цель обзора: определить механизмы развития легочной гипертензии у детей, страдающих бронхолегочной дисплазией.

Основные положения

Основные положения. Патогенез бронхолегочной дисплазии в настоящее время остается до конца не изученным. Важную роль играют изменения в передаче внутриклеточных сигналов, влияющих на регуляцию ангиогенеза. Гипоксия, гипероксия и воздействие искусственной вентиляции легких приводят к оксидативному и воспалительному стрессу, вызывая повреждение в альвеолах легких и сосудистой сети с развитием легочной гипертензии. Необходимо понимание взаимодействия факторов роста, факторов транскрипции и воспалительных процессов, регулирующих нормальное развитие паренхимы и микрососудистого русла легких для разработки превентивных подходов.

Заключение

Заключение. Дальнейшее изучение роли значимых биомаркеров формирования бронхолегочной дисплазии может помочь в ранней диагностике и профилактике развития этого заболевания, а также такого грозного его осложнения, как легочная гипертензия.

Objective of the Review

Objective of the Review: To determine the mechanisms of development of pulmonary hypertension in children suffering from bronchopulmonary dysplasia.

Key points

Key points. The pathogenesis of bronchopulmonary dysplasia is currently not fully understood. Changes in the transmission of intracellular signals affecting the regulation of angiogenesis play an important role. Hypoxia, hyperoxia, and exposure to mechanical ventilation lead to oxidative and inflammatory stress, causing damage to the lung alveoli and vasculature with the development of pulmonary hypertension. It is necessary to understand the interaction of growth factors, transcription factors and inflammatory processes that regulate the normal development of the parenchyma and microvascular bed of the lungs to develop preventive methods.

Conclusion

Conclusion. Further study of the role of significant biomarkers of the formation of bronchopulmonary dysplasia can help in the early diagnosis and prevention of the development of this disease, as well as such a threatening complication as pulmonary hypertension.

недоношенностьбронхолегочная дисплазиялегочная гипертензиябиомаркеры ангиогенезаprematuritybronchopulmonary dysplasiapulmonary hypertensionangiogenesis biomarkersReferencesSahni M., Bhandari V. Patho-mechanisms of the origins of bronchopulmonary dysplasia. Mol. Cell Pediatr. 2021; 8: 21. DOI: 10.1186/s40348-021-00129-5Sahni M., Bhandari V. Patho-mechanisms of the origins of bronchopulmonary dysplasia. Mol. Cell Pediatr. 2021; 8: 21. DOI: 10.1186/s40348-021-00129-5Hansmann G., Sallmon H., Roehr C.C., Kourembanas S. et al. European Pediatric Pulmonary Vascular Disease Network (EPPVDN). Pulmonary hypertension in bronchopulmonary dysplasia. Pediatr. Res. 2021; 89(3): 446–55. DOI: 10.1038/s41390-020-0993-4Hansmann G., Sallmon H., Roehr C.C., Kourembanas S. et al. European Pediatric Pulmonary Vascular Disease Network (EPPVDN). Pulmonary hypertension in bronchopulmonary dysplasia. Pediatr. Res. 2021; 89(3): 446–55. DOI: 10.1038/s41390-020-0993-4Mathew R. Signaling pathways involved in the development of bronchopulmonary dysplasia and pulmonary hypertension. Children (Basel). 2020; 7(8): 100. DOI: 10.3390/children7080100Mathew R. Signaling pathways involved in the development of bronchopulmonary dysplasia and pulmonary hypertension. Children (Basel). 2020; 7(8): 100. DOI: 10.3390/children7080100Chen S., Rong M., Platteau A., Hehre D. et al. CTGF disrupts alveolarization and induces pulmonary hypertension in neonatal mice: implication in the pathogenesis of severe bronchopulmonary dysplasia. Am. J. Physiol. Lung Cell Mol. Physiol. 2011; 300(3): L330–40. DOI: 10.1152/ajplung.00270.2010Chen S., Rong M., Platteau A., Hehre D. et al. CTGF disrupts alveolarization and induces pulmonary hypertension in neonatal mice: implication in the pathogenesis of severe bronchopulmonary dysplasia. Am. J. Physiol. Lung Cell Mol. Physiol. 2011; 300(3): L330–40. DOI: 10.1152/ajplung.00270.2010Stark A., Dammann C., Nielsen H.C., Volpe M.V. A pathogenic relationship of bronchopulmonary dysplasia and retinopathy of prematurity? A review of angiogenic mediators in both diseases. Front. Pediatr. 2018; 6: 125. DOI: 10.3389/fped.2018.00125Stark A., Dammann C., Nielsen H.C., Volpe M.V. A pathogenic relationship of bronchopulmonary dysplasia and retinopathy of prematurity? A review of angiogenic mediators in both diseases. Front. Pediatr. 2018; 6: 125. DOI: 10.3389/fped.2018.00125Hilgendorff A., Reiss I., Ehrhardt H., Eickelberg O. et al. Chronic lung disease in the preterm infant. Lessons learned from animal models. Am. J. Respir. Cell Mol. Biol. 2014; 50(2): 233–45. DOI: 10.1165/rcmb.2013-0014TRHilgendorff A., Reiss I., Ehrhardt H., Eickelberg O. et al. Chronic lung disease in the preterm infant. Lessons learned from animal models. Am. J. Respir. Cell Mol. Biol. 2014; 50(2): 233–45. DOI: 10.1165/rcmb.2013-0014TRSalaets T., Gie A., Tack B., Deprest J. et al. Modelling bronchopulmonary dysplasia in animals: arguments for the preterm rabbit model. Curr. Pharm. Des. 2017; 23(38): 5887–901. DOI: 10.2174/1381612823666170926123550Salaets T., Gie A., Tack B., Deprest J. et al. Modelling bronchopulmonary dysplasia in animals: arguments for the preterm rabbit model. Curr. Pharm. Des. 2017; 23(38): 5887–901. DOI: 10.2174/1381612823666170926123550Mandell E.W., Abman S.H. Fetal vascular origins of bronchopulmonary dysplasia. J Pediatr. 2017; 185: 7–10.e1. DOI: 10.1016/j.jpeds.2017.03.024Mandell E.W., Abman S.H. Fetal vascular origins of bronchopulmonary dysplasia. J Pediatr. 2017; 185: 7–10.e1. DOI: 10.1016/j.jpeds.2017.03.024Morrow L.A., Wagner B.D., Ingram D.A., Poindexter B.B. et al. Antenatal determinants of bronchopulmonary dysplasia and late respiratory disease in preterm infants. Am. J. Respir. Crit. Care Med. 2017; 196(3): 364–74. DOI: 10.1164/rccm.201612-2414OCMorrow L.A., Wagner B.D., Ingram D.A., Poindexter B.B. et al. Antenatal determinants of bronchopulmonary dysplasia and late respiratory disease in preterm infants. Am. J. Respir. Crit. Care Med. 2017; 196(3): 364–74. DOI: 10.1164/rccm.201612-2414OCMestan K.K., Gotteiner N., Prota N., Grobman W. et al. Cord blood biomarkers of placental maternal vascular underperfusion predict bronchopulmonary dysplasia-associated pulmonary hypertension. J. Pediatr. 2017; 185: 33–41. DOI: 10.1016/j.jpeds.2017.01.015Mestan K.K., Gotteiner N., Prota N., Grobman W. et al. Cord blood biomarkers of placental maternal vascular underperfusion predict bronchopulmonary dysplasia-associated pulmonary hypertension. J. Pediatr. 2017; 185: 33–41. DOI: 10.1016/j.jpeds.2017.01.015Wallace B., Peisl A., Seedorf G., Nowlin T. et al. Anti-sFlt-1 therapy preserves lung alveolar and vascular growth in antenatal models of bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 2018; 197(6): 776–87. DOI: 10.1164/rccm.201707-1371OCWallace B., Peisl A., Seedorf G., Nowlin T. et al. Anti-sFlt-1 therapy preserves lung alveolar and vascular growth in antenatal models of bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 2018; 197(6): 776–87. DOI: 10.1164/rccm.201707-1371OCVillamor-Martinez E., Álvarez-Fuente M., Ghazi A.M.T., Degraeuwe P. Association of chorioamnionitis with bronchopulmonary dysplasia among preterm infants: a systematic review, meta-analysis, and metaregression. JAMA Netw. Open. 2019; 2(11): e1914611. DOI: 10.1001/jamanetworkopen.2019.14611Villamor-Martinez E., Álvarez-Fuente M., Ghazi A.M.T., Degraeuwe P. Association of chorioamnionitis with bronchopulmonary dysplasia among preterm infants: a systematic review, meta-analysis, and metaregression. JAMA Netw. Open. 2019; 2(11): e1914611. DOI: 10.1001/jamanetworkopen.2019.14611Watterberg K.L., Demers L.M., Scott S.M., Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics. 1996; 97(2): 210–5.Watterberg K.L., Demers L.M., Scott S.M., Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics. 1996; 97(2): 210–5.Willems M.G.M., Kemp M.W., Fast L.A., Wagemaker N.M.M. et al. Pulmonary vascular changes in extremely preterm sheep after intra amniotic exposure to Ureaplasma parvum and lipopolysaccharide. PLoS One. 2017; 12(6): e0180114. DOI: 10.1371/journal.pone.0180114Willems M.G.M., Kemp M.W., Fast L.A., Wagemaker N.M.M. et al. Pulmonary vascular changes in extremely preterm sheep after intra amniotic exposure to Ureaplasma parvum and lipopolysaccharide. PLoS One. 2017; 12(6): e0180114. DOI: 10.1371/journal.pone.0180114Been J.V., Debeer A., van Iwaarden J.F., Kloosterboer N. et al. Early alterations of growth factor patterns in bronchoalveolar lavage fluid from preterm infants developing bronchopulmonary dysplasia. Pediatr. Res. 2010; 67(1): 83–9. DOI: 10.1203/PDR.0b013e3181c13276Been J.V., Debeer A., van Iwaarden J.F., Kloosterboer N. et al. Early alterations of growth factor patterns in bronchoalveolar lavage fluid from preterm infants developing bronchopulmonary dysplasia. Pediatr. Res. 2010; 67(1): 83–9. DOI: 10.1203/PDR.0b013e3181c13276Dumas de la Roque E., Smeralda G., Quignard J.F., Freund-Michel V. et al. Altered vasoreactivity in neonatal rats with pulmonary hypertension associated with bronchopulmonary dysplasia: Implication of both eNOS phosphorylation and calcium signaling. PLoS One. 2017; 12(2): e0173044. DOI: 10.1371/journal.pone.0173044Dumas de la Roque E., Smeralda G., Quignard J.F., Freund-Michel V. et al. Altered vasoreactivity in neonatal rats with pulmonary hypertension associated with bronchopulmonary dysplasia: Implication of both eNOS phosphorylation and calcium signaling. PLoS One. 2017; 12(2): e0173044. DOI: 10.1371/journal.pone.0173044Melincovici C.S., Boşca A.B., Şuşman S., Mărginean M. et al. Vascular endothelial growth factor (VEGF) — key factor in normal and patholo gical angiogenesis. Rom. J. Morphol. Embryol. 2018; 59(2): 455–67.Melincovici C.S., Boşca A.B., Şuşman S., Mărginean M. et al. Vascular endothelial growth factor (VEGF) — key factor in normal and patholo gical angiogenesis. Rom. J. Morphol. Embryol. 2018; 59(2): 455–67.Syed M., Das P., Pawar A., Aghai Z.H. et al. Hyperoxia causes miR 34a-mediated injury via angiopoietin-1 in neonatal lungs. Nat. Commun. 2017; 8(1): 1173. DOI: 10.1038/s41467-017-01349-ySyed M., Das P., Pawar A., Aghai Z.H. et al. Hyperoxia causes miR 34a-mediated injury via angiopoietin-1 in neonatal lungs. Nat. Commun. 2017; 8(1): 1173. DOI: 10.1038/s41467-017-01349-yKim D.-H., Kim H.-S. Serial changes of serum endostatin and angiopoietin-1 levels in preterm infants with severe bronchopulmonary dysplasia and subsequent pulmonary artery hypertension. Neonatology. 2014; 106(1): 55–61. DOI: 10.1159/000358374Kim D.-H., Kim H.-S. Serial changes of serum endostatin and angiopoietin-1 levels in preterm infants with severe bronchopulmonary dysplasia and subsequent pulmonary artery hypertension. Neonatology. 2014; 106(1): 55–61. DOI: 10.1159/000358374Salimi U., Menden H.L., Mabry S.M., Xia S. et al. Angiopoietin-1 protects against endotoxin-induced neonatal lung injury and alveolar simplification in mice. Pediatr. Res. 2022; 91(6): 1405–15. DOI: 10.1038/s41390-021-01544-0Salimi U., Menden H.L., Mabry S.M., Xia S. et al. Angiopoietin-1 protects against endotoxin-induced neonatal lung injury and alveolar simplification in mice. Pediatr. Res. 2022; 91(6): 1405–15. DOI: 10.1038/s41390-021-01544-0Shafiee A., Penn J.S., Krutzsch H.C., Inman J.K. et al. Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1. Invest. Ophthalmol. Vis. Sci. 2000; 41(8): 2378–88. 22. Oak P., Hilgendorff A. The BPD trio? Interaction of dysregulated PDGF, VEGF, and TGF signaling in neonatal chronic lung disease. Mol. Cell Pediatr. 2017; 4(1): 11. DOI: 10.1186/s40348-017-0076-8Shafiee A., Penn J.S., Krutzsch H.C., Inman J.K. et al. Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1. Invest. Ophthalmol. Vis. Sci. 2000; 41(8): 2378–88. 22. Oak P., Hilgendorff A. The BPD trio? Interaction of dysregulated PDGF, VEGF, and TGF signaling in neonatal chronic lung disease. Mol. Cell Pediatr. 2017; 4(1): 11. DOI: 10.1186/s40348-017-0076-8De Paepe M.E., Mao Q., Powell J., Rubin S.E. et al. Growth of pulmonary microvasculature in ventilated preterm infants. Am. J. Respir. Crit. Care Med. 2006; 173(2): 204–11. DOI: 10.1164/rccm.200506-927OCDe Paepe M.E., Mao Q., Powell J., Rubin S.E. et al. Growth of pulmonary microvasculature in ventilated preterm infants. Am. J. Respir. Crit. Care Med. 2006; 173(2): 204–11. DOI: 10.1164/rccm.200506-927OCRebetz J., Semple J.W., Kapur R. The pathogenic involvement of neutrophils in acute respiratory distress syndrome and transfusion related acute lung injury. Transfus. Med. Hemother. 2018; 45(5): 290–8. DOI: 10.1159/000492950Rebetz J., Semple J.W., Kapur R. The pathogenic involvement of neutrophils in acute respiratory distress syndrome and transfusion related acute lung injury. Transfus. Med. Hemother. 2018; 45(5): 290–8. DOI: 10.1159/000492950Collaco J.M., McGrath-Morrow S.A., Griffiths M., Chavez-Valdez R. et al. Perinatal inflammatory biomarkers and respiratory disease in preterm infants. J. Pediatr. 2022; 246: 34–9.e3. DOI: 10.1016/j.jpeds.2022.04.028Collaco J.M., McGrath-Morrow S.A., Griffiths M., Chavez-Valdez R. et al. Perinatal inflammatory biomarkers and respiratory disease in preterm infants. J. Pediatr. 2022; 246: 34–9.e3. DOI: 10.1016/j.jpeds.2022.04.028El Agha E., Moiseenko A., Kheirollahi V., De Langhe S. e al. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem. Cell. 2017; 20(2): 261–73.e3. DOI: 10.1016/j.stem.2016.10.004El Agha E., Moiseenko A., Kheirollahi V., De Langhe S. e al. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem. Cell. 2017; 20(2): 261–73.e3. DOI: 10.1016/j.stem.2016.10.004Chao C.M., Moiseenko A., Kosanovic D., Rivetti, S. et al. Impact of Fgf10 deficiency on pulmonary vasculature formation in a mouse model of bronchopulmonary dysplasia. Hum. Mol. Genet. 2019; 28(9): 1429 44. DOI: 10.1093/hmg/ddy439Chao C.M., Moiseenko A., Kosanovic D., Rivetti, S. et al. Impact of Fgf10 deficiency on pulmonary vasculature formation in a mouse model of bronchopulmonary dysplasia. Hum. Mol. Genet. 2019; 28(9): 1429 44. DOI: 10.1093/hmg/ddy439Chao C.M., Yahya F., Moiseenko A., Tiozzo C. et al. Fgf10 deficiency is causative for lethality in a mouse model of bronchopulmonary dysplasia. J. Pathol. 2017; 241(1): 91–103. DOI: 10.1002/path.4834Chao C.M., Yahya F., Moiseenko A., Tiozzo C. et al. Fgf10 deficiency is causative for lethality in a mouse model of bronchopulmonary dysplasia. J. Pathol. 2017; 241(1): 91–103. DOI: 10.1002/path.4834Бондарь В.А., Давыдова И.В., Басаргина М.А., Фисенко А.П. и др. Роль генетических предикторов в доклинической диагностике бронхолегочной дисплазии Кремлевская медицина. 2022; 1: 5–9. [Bondar V.A., Davydova I.V., Basargina M.A., Fisenco A.P. et al. The role of genetic predictors in preclinical diagnostics of bronchopulmonary dysplasia. Kremlin Medicine Journal. 2022; 1: 5–9. (in Russian)]. DOI: 10.26269/m7zs-qa3Бондарь В.А., Давыдова И.В., Басаргина М.А., Фисенко А.П. и др. Роль генетических предикторов в доклинической диагностике бронхолегочной дисплазии Кремлевская медицина. 2022; 1: 5–9. [Bondar V.A., Davydova I.V., Basargina M.A., Fisenco A.P. et al. The role of genetic predictors in preclinical diagnostics of bronchopulmonary dysplasia. Kremlin Medicine Journal. 2022; 1: 5–9. (in Russian)]. DOI: 10.26269/m7zs-qa3Ren Y., Lyu Y., Mereness J.A., Wang S. et al. Rare pulmonary connective tissue type mast cells regulate lung endothelial cell angiogenesis. Am. J. Pathol. 2020; 190(8): 1763–73. DOI: 10.1016/j.ajpath.2020.04.017Ren Y., Lyu Y., Mereness J.A., Wang S. et al. Rare pulmonary connective tissue type mast cells regulate lung endothelial cell angiogenesis. Am. J. Pathol. 2020; 190(8): 1763–73. DOI: 10.1016/j.ajpath.2020.04.017Winter N.A., Gibson P.G., McDonald V.M., Fricker M. Sputum gene expression reveals dysregulation of mast cells and basophils in eosinophilic COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2021; 16: 2165–79. DOI: 10.2147/COPD.S305380Winter N.A., Gibson P.G., McDonald V.M., Fricker M. Sputum gene expression reveals dysregulation of mast cells and basophils in eosinophilic COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2021; 16: 2165–79. DOI: 10.2147/COPD.S305380Ramazani Y., Knops N., Elmonem M.A., Nguyen T.Q. et al. Connective tissue growth factor (CTGF) from basics to clinics. Matrix Biol. 2018; 68–69: 44–66. DOI: 10.1016/j.matbio.2018.03.007Ramazani Y., Knops N., Elmonem M.A., Nguyen T.Q. et al. Connective tissue growth factor (CTGF) from basics to clinics. Matrix Biol. 2018; 68–69: 44–66. DOI: 10.1016/j.matbio.2018.03.007Wang X., Cui H., Wu S. CTGF: a potential therapeutic target for bronchopulmonary dysplasia. Eur. J. Pharmacol. 2019; 860: 172588. DOI: 10.1016/j.ejphar.2019.172588Wang X., Cui H., Wu S. CTGF: a potential therapeutic target for bronchopulmonary dysplasia. Eur. J. Pharmacol. 2019; 860: 172588. DOI: 10.1016/j.ejphar.2019.172588Wu S., Platteau A., Chen S., McNamara G. et al. Conditional overexpression of connective tissue growth factor disrupts postnatal lung development. Am. J. Respir. Cell Mol. Biol. 2010; 42(5): 552–63. DOI: 10.1165/rcmb.2009-0068OCWu S., Platteau A., Chen S., McNamara G. et al. Conditional overexpression of connective tissue growth factor disrupts postnatal lung development. Am. J. Respir. Cell Mol. Biol. 2010; 42(5): 552–63. DOI: 10.1165/rcmb.2009-0068OCMcDonald P.C., Fielding A.B., Dedhar S. Integrin-linked kinase — essential roles in physiology and cancer biology. J. Cell Sci. 2008; 121(pt19): 3121–32. DOI: 10.1242/jcs.017996McDonald P.C., Fielding A.B., Dedhar S. Integrin-linked kinase — essential roles in physiology and cancer biology. J. Cell Sci. 2008; 121(pt19): 3121–32. DOI: 10.1242/jcs.017996Varghese S., Braggio D.A., Gillespie J., Toland A.E. et al. TGF-β and CTGF are mitogenic output mediators of wnt/β-catenin signaling in desmoid fibromatosis. Appl. Immunohistochem. Mol. Morphol. 2017; 25(8): 559–65. DOI: 10.1097/PAI.0000000000000340Varghese S., Braggio D.A., Gillespie J., Toland A.E. et al. TGF-β and CTGF are mitogenic output mediators of wnt/β-catenin signaling in desmoid fibromatosis. Appl. Immunohistochem. Mol. Morphol. 2017; 25(8): 559–65. DOI: 10.1097/PAI.0000000000000340Kim H.T., Panza P., Kikhi K., Nakamichi Y. et al. WNT/RYK signaling functions as an antiinflammatory modulator in the lung mesen chyme. Proc. Natl. Acad. Sci. USA. 2022; 119(24): e2201707119. DOI: 10.1073/pnas.2201707119Kim H.T., Panza P., Kikhi K., Nakamichi Y. et al. WNT/RYK signaling functions as an antiinflammatory modulator in the lung mesen chyme. Proc. Natl. Acad. Sci. USA. 2022; 119(24): e2201707119. DOI: 10.1073/pnas.2201707119Alapati D., Rong M., Chen S., Hehre D. et al. Connective tissue growth factor antibody therapy attenuates hyperoxia-induced lung injury in neonatal rats. Am. J. Respir. Cell Mol. Biol. 2011; 45(6): 1169–77. DOI: 10.1165/rcmb.2011-0023OCAlapati D., Rong M., Chen S., Hehre D. et al. Connective tissue growth factor antibody therapy attenuates hyperoxia-induced lung injury in neonatal rats. Am. J. Respir. Cell Mol. Biol. 2011; 45(6): 1169–77. DOI: 10.1165/rcmb.2011-0023OCMathew R. Signaling pathways involved in the development of bronchopulmonary dysplasia and pulmonary hypertension. Children (Basel). 2020; 7(8): 100. DOI: 10.3390/children7080100Mathew R. Signaling pathways involved in the development of bronchopulmonary dysplasia and pulmonary hypertension. Children (Basel). 2020; 7(8): 100. DOI: 10.3390/children7080100Yanagihara T., Tsubouchi K., Gholiof M., Chong S.G. et al. Connective tissue growth factor contributes to TGF-β1-induced lung fibrosis. Am. J. Respir. Cell Mol. Biol. 2022; 66(3): 260–70. DOI: 10.1165/rcmb.2020-0504OCYanagihara T., Tsubouchi K., Gholiof M., Chong S.G. et al. Connective tissue growth factor contributes to TGF-β1-induced lung fibrosis. Am. J. Respir. Cell Mol. Biol. 2022; 66(3): 260–70. DOI: 10.1165/rcmb.2020-0504OCInoki I., Shiomi T., Hashimoto G., Enomoto H. et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 2002; 16(2): 219–21. DOI: 10.1096/fj.01-0332fjeInoki I., Shiomi T., Hashimoto G., Enomoto H. et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 2002; 16(2): 219–21. DOI: 10.1096/fj.01-0332fjePi L., Fu C., Lu Y., Zhou J. et al. Vascular endothelial cell-specific connective tissue growth factor (CTGF) is necessary for development of chronic hypoxia-induced pulmonary hypertension. Front. Physiol. 2018; 9: 138. DOI: 10.3389/fphys.2018.00138Pi L., Fu C., Lu Y., Zhou J. et al. Vascular endothelial cell-specific connective tissue growth factor (CTGF) is necessary for development of chronic hypoxia-induced pulmonary hypertension. Front. Physiol. 2018; 9: 138. DOI: 10.3389/fphys.2018.00138Speer C.P. Inflammation and bronchopulmonary dysplasia: a continuing story. Semin. Fetal Neonatal Med. 2006; 11(5): 354–62. DOI: 10.1016/j.siny.2006.03.004Speer C.P. Inflammation and bronchopulmonary dysplasia: a continuing story. Semin. Fetal Neonatal Med. 2006; 11(5): 354–62. DOI: 10.1016/j.siny.2006.03.004Kuiper E.J., Roestenberg P., Ehlken C., Lambert V. et al. Angiogenesis is not impaired in connective tissue growth factor (CTGF) knock out mice. J. Histochem. Cytochem. 2007; 55(11): 1139–47. DOI: 10.1369/jhc.7A7258.2007Kuiper E.J., Roestenberg P., Ehlken C., Lambert V. et al. Angiogenesis is not impaired in connective tissue growth factor (CTGF) knock out mice. J. Histochem. Cytochem. 2007; 55(11): 1139–47. DOI: 10.1369/jhc.7A7258.2007Grover T.R., Parker T.A., Zenge J.P., Markham N.E. et al. Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am. J. Physiol. Lung Cell Mol. Physiol. 2003; 284(3): L508–17. DOI: 10.1152/ajplung.00135.2002Grover T.R., Parker T.A., Zenge J.P., Markham N.E. et al. Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am. J. Physiol. Lung Cell Mol. Physiol. 2003; 284(3): L508–17. DOI: 10.1152/ajplung.00135.2002

The authors declare that there are no conflicts of interest present.